Back to search
Symptomatic Vitreomacular Adhesion (VMA)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Symptomatic Vitreomacular Adhesion (VMA) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Symptomatic Vitreomacular Adhesion (VMA) trials you may qualify forEvaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocri…
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.
This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting f…
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
Vitreomacular adhesion causes symptoms of blurry vision, distortion, and double vision. It is due to an abnormal separation of the vitreous gel from the surface…
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocripla…
The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment…